David Meeker, MD
Dr. Meeker has served as a member of our Board of Directors since November 2015. He is President and Chief Executive Officer of KSQ Therapeutics. Previously, Dr. Meeker was President and Chief Executive Officer of Genzyme, a Sanofi company, a position he assumed when Genzyme was acquired by Sanofi in 2011. In that capacity, he provided oversight and vision for Genzyme’s two business units—rare diseases and multiple sclerosis—as well as the company’s relationships with patient communities and the company’s workforce of nearly 6,000 employees. Prior to Genzyme’s merger with Sanofi, Dr. Meeker was Genzyme’s Chief Operating Officer, responsible for the company’s commercial organization and for overseeing its business units, country management organization, and global market access functions. Dr. Meeker joined Genzyme in 1994 as Medical Director to work on the Cystic Fibrosis Gene Therapy program. Subsequently, as Vice President, Medical Affairs, he was responsible for the development of rare disease therapies that today represent transformative and lifesaving advancements in medicine for patients. Prior to joining Genzyme, Dr. Meeker was Director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an Assistant Professor of Medicine at Ohio State University. Dr. Meeker received his MD from the University of Vermont Medical School. He completed the Advanced Management Program at Harvard Business School.